Form 8-K - Current report:
SEC Accession No. 0000950170-22-000036
Filing Date
2022-01-04
Accepted
2022-01-04 16:06:20
Documents
15
Period of Report
2021-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bdsx-20211230.htm   iXBRL 8-K 59364
2 EX-10.40 bdsx-ex10_40.htm EX-10.40 172819
3 EX-99.1 bdsx-ex99_1.htm EX-99.1 17458
4 GRAPHIC img189760734_0.jpg GRAPHIC 2870
  Complete submission text file 0000950170-22-000036.txt   407769

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bdsx-20211230_lab.xml EX-101.LAB 18612
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bdsx-20211230.xsd EX-101.SCH 2488
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bdsx-20211230_pre.xml EX-101.PRE 11596
9 EXTRACTED XBRL INSTANCE DOCUMENT bdsx-20211230_htm.xml XML 4886
Mailing Address 2970 WILDERNESS PLACE SUITE 100 BOULDER CO 80301
Business Address 2970 WILDERNESS PLACE SUITE 100 BOULDER CO 80301 303-417-0500
BIODESIX INC (Filer) CIK: 0001439725 (see all company filings)

EIN.: 203986492 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39659 | Film No.: 22505827
SIC: 8071 Services-Medical Laboratories